资料显示，长春高新技术产业(集团)股份有限公司位于吉林省长春市高新海容广场B座27层(震宇街与东 蔚山路交汇)，成立日期1993年6月10日，上市日期1996年12月18日，公司主营业务涉及生物制药及中成 药的研发、生产和销售,辅以房地产开发、物业管理和服务等业务。主营业务收入构成为：制药业 92.83%，房地产6.81%，服务业0.36%。 从长春高新十大流通股东角度 数据显示，华泰柏瑞基金旗下1只基金位居长春高新十大流通股东。华泰柏瑞沪深300ETF（510300）二 季度增持73.16万股，持有股数576.21万股，占流通股的比例为1.44%。根据测算，今日浮盈赚取约 3699.27万元。 华泰柏瑞沪深300ETF（510300）成立日期2012年5月4日，最新规模3747.04亿。今年以来收益18.19%， 同类排名2916/4222；近一年收益47.33%，同类排名2296/3804；成立以来收益111.48%。 9月18日，长春高新涨5.18%，截至发稿，报130.30元/股，成交15.27亿元，换手率3.00%，总市值531.54 亿元。 华泰柏瑞沪深300ETF（510300）基金经理为柳军。 ...

Group 1 - Dagan Holdings' shareholder plans to reduce holdings by up to 3% of the company's shares, totaling approximately 9.52 million shares [1] - China Resources Sanjiu intends to invest up to 10 billion yuan of its own funds in bank wealth management products, with a rolling investment strategy [1] - Xinyu Guoke's shareholder plans to reduce holdings by up to 1% of the company's shares, totaling approximately 276.76 thousand shares [3] Group 2 - Tianpu Co. has completed the stock trading suspension review and will resume trading after a period of abnormal price fluctuations [5] - Xinhang New Materials' controlling shareholder plans to reduce holdings by up to 2% of the company's shares, totaling approximately 174.88 thousand shares [6] - Yinbang Co.'s shareholder plans to reduce holdings by up to 3% of the company's shares, totaling approximately 24.66 million shares [7] Group 3 - Yuanfei Pet's shareholders plan to collectively reduce holdings by up to 3.48% of the company's shares, totaling approximately 565.14 thousand shares [7] - Changchun High-tech's subsidiary will gain exclusive agency rights for three products in mainland China [9] - Hanyi Co.'s controlling shareholder plans to reduce holdings by up to 3% of the company's shares, totaling approximately 294 thousand shares [10] Group 4 - Zhongcai Energy's subsidiary signed a total contract worth 347 million yuan for a project in Hubei Province [11] - Ruifeng Bank's shareholder reduced holdings by 408.83 thousand shares, decreasing their ownership from 6.10% to 5.89% [12] - Shanghai Construction's gold business revenue is low, accounting for less than 0.5% of total revenue [13] Group 5 - Guanggang Gas's shareholder plans to reduce holdings by up to 2.63 million shares, approximately 1.9994% of the company's total shares [14] - Kairun Co.'s controlling shareholder has decided to terminate the share reduction plan early [15] - Boyun New Materials' shareholder plans to reduce holdings by up to 1% of the company's shares, totaling approximately 573 thousand shares [16] Group 6 - Yuanda Environmental's acquisition of assets and fundraising has been approved by the Shanghai Stock Exchange [17] - ST Ningke's stock will be subject to delisting risk warning due to the company's restructuring [18] - Anke Biotech's investee company has received approval for a key II phase clinical trial for a new injection [19] Group 7 - Shuanglu Pharmaceutical's director plans to reduce holdings by up to 37.52 thousand shares, approximately 0.0365% of the company's total shares [20] - Zhongji Xuchuang's specific shareholder's holding ratio changed by more than 1% [21] - ST Nanzhi plans to sell real estate development and leasing business assets for 1 yuan to focus on urban operation [22]

新京报贝壳财经讯（记者俞金旻）9月17日晚，长春高新发布公告称，控股子公司金赛药业与丹麦ALK- AbellóA/S公司在上海达成变应原特异性免疫治疗(AIT)产品合作，将在中国联合开发并商业化ALK的屋 尘螨(HDM)变应原特异性免疫治疗产品，并获得ALK自主开发的3款产品在中国大陆范围内的独家代理 权益。 根据协议，金赛药业将支付首付款3270万欧元，针对尘螨变应原舌下片(ACARIZAX )成人、青少年及 儿童适应症在中国区域内药品监管部门的临床试验监管审批进展，金赛药业将后续支付注册里程碑付款 4000万欧元。 未来，根据上述产品在中国市场的销售情况，金赛药业或后续支付销售里程碑1.05亿欧元。据Fortune Business Insights报告，全球过敏免疫治疗市场规模预计到2030年将达到32亿美元，复合年增长率为 9.5%。中国拥有全球尘螨过敏患者最大的患者人群，但中国过敏免疫疗法市场开发不足、缺乏创新产 品。目前接受脱敏治疗的患者数量不足100万，存在大量未满足临床需求。 编辑 杨娟娟 校对 赵琳 ...

新华财经上海9月18日电（记者胡洁菲）长春高新控股子公司长春金赛药业有限责任公司17日晚间与全 球头部脱敏治疗药企ALK-Abelló A/S公司签署合作协议，双方达成变应原特异性免疫治疗（AIT，俗称 脱敏治疗）产品合作，将在中国联合开发并商业化 ALK 的变应原特异性免疫治疗产品；同时，金赛药 业将获得ALK自主开发的3款脱敏治疗相关产品在中国大陆范围的独家代理权益。 根据相关公告，金赛药业将获得ALK皮下注射用屋尘螨变应原制剂（安脱达®）、螨变应原皮肤点刺试 剂盒（安刺®）及尘螨变应原舌下片（ACARIZAX®）在中国大陆的独家权益，合作权益期限至2039年 12月31日止；金赛药业还将于下月起接手ALK在中国大陆已上市合作产品的销售与市场推广工作，并 由双方合作完成目前正在进行的尘螨变应原舌下片临床开发工作，并在其获得药品监管机构批准后，负 责其在合作区域内的销售及市场推广。 据Fortune Business Insights报告，全球过敏免疫治疗市场规模预计到2030年将达到32亿美元，复合年增 长率为9.5%。 丹麦上市药企ALK是全球头部脱敏治疗公司，全球市占率超45%，拥有多项全球首创产品。 ...

Macro News - The U.S. Treasury reported that from January to August, the national general public budget revenue reached 14,819.8 billion yuan, a year-on-year increase of 0.3% [2] - The securities transaction stamp duty for the same period was 118.7 billion yuan, showing a significant year-on-year increase of 81.7% [2] - In August, the securities transaction stamp duty increased by 226% year-on-year and 66% month-on-month [2] Industry News - The Ministry of Industry and Information Technology is soliciting opinions on the mandatory national standard for "Intelligent Connected Vehicles Combination Driving Assistance System Safety Requirements," which includes features for detecting driver disengagement [3] - The total A-share trading volume for the year has reached 280 trillion yuan, a 109% increase compared to the same period last year [3] - The average daily trading volume in A-shares is 16.1 trillion yuan, up 107% year-on-year [3] - The China Nonferrous Metals Industry Association reported that the transaction price range for multi-crystalline silicon n-type raw materials is 51,000 to 55,000 yuan per ton, with an average transaction price of 53,200 yuan per ton, reflecting an 8.57% increase [4] Company News - Tianpu Co. announced that there is uncertainty regarding the change of control, and its stock will resume trading on September 18 [11] - Hengrui Medicine announced that its application for a new indication for the injection of Rukang Qumizhuo monoclonal antibody for breast cancer patients has been accepted and prioritized for review [11] - China Ping An announced the completion of its long-term service plan for stock purchases for the year 2025 [11] - Top Group announced that its actual controller and vice chairman has terminated the share reduction plan ahead of schedule [11] - Huazhu Group announced a planned investment of no more than 10 billion yuan in bank wealth management products [11]

Group 1 - The company held its 13th meeting of the 11th Board of Directors on September 17, 2025, with all 9 directors participating in the voting [2][4][5] - The meeting approved a proposal for a collaboration between the subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., and Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China [7][8][11] Group 2 - The collaboration includes exclusive rights for three products developed by ALK in mainland China, which are a subcutaneous injection for house dust mite allergens, a sublingual tablet for allergic asthma and rhinitis, and a skin prick test kit for mite allergens [12][14] - The agreement stipulates a total initial payment of €32.7 million, with additional milestone payments based on regulatory progress and sales performance, potentially totaling €105 million [15][16] Group 3 - ALK is a global specialty pharmaceutical company focused on allergy and asthma treatments, with a significant market share exceeding 45% in the allergen immunotherapy sector [13] - The partnership aims to leverage the growing market potential in China, where the prevalence of dust mite allergies is high but treatment penetration remains low, with less than 1 million patients currently receiving allergen-specific immunotherapy [16]

迈威生物公告称，公司与Kalexo Bio,Inc.就2MW7141项目相关签署《独家许可协议》及《优先股股权购 买协议》。根据许可协议，迈威生物许可Kalexo在全球范围独家开发、生产和商业化以及其他方式开发 许可产品的权利。交易金额方面，迈威生物将从Kalexo获得最高可达10亿美元的预付款和里程碑付款， 以及低个位数的特许权使用费，其中包括一次性、不可返还的首付款及近端付款1,200万美元现金。作 为对价的一部分，迈威生物将在符合约定条件下另外获得Kalexo总计双位数的A轮优先股。此次交易预 计将对公司未来业绩产生积极影响，有利于提升公司的盈利能力。2MW7141是公司自主研发的一款处 于临床前阶段的双靶点小核酸药物，主要针对血脂异常人群的血脂调控以及高危心血管事件的预防。 恒瑞医药：注射用瑞康曲妥珠单抗新适应症上市申请获受理并纳入优先审评 恒瑞医药公告称，公司子公司苏州盛迪亚生物医药有限公司收到国家药监局下发的《受理通知书》，公 司注射用瑞康曲妥珠单抗（SHR—A1811）用于治疗既往接受过一种或一种以上抗HER2药物治疗的局 部晚期或转移性HER2阳性成人乳腺癌患者的新适应症上市许可申请获国家药监 ...

Core Viewpoint - Changchun Jinsai Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with ALK-Abelló A/S to jointly develop and commercialize allergen-specific immunotherapy products in China, enhancing the market presence of desensitization treatments in the region [1][2]. Group 1: Partnership Details - The collaboration includes two allergen-specific immunotherapy products and one skin prick test kit developed by ALK [3]. - Jinsai Pharmaceutical will have exclusive rights to sell ALK's subcutaneous dust mite allergen preparation (Andorra), skin prick test kit (Anci), and sublingual tablet (ACARIZAX) in mainland China until December 31, 2039 [3]. - Starting from October 1, 2025, Jinsai will take over the sales and marketing of ALK's already launched products in mainland China and will collaborate on the clinical development of ACARIZAX [3]. Group 2: Market Potential - The global allergy immunotherapy market is projected to reach $3.2 billion by 2030, with a compound annual growth rate (CAGR) of 9.5% [3]. - China has the largest population of dust mite allergy patients globally, yet the market for allergy immunotherapy remains underdeveloped, with fewer than 1 million patients currently receiving desensitization treatment [3]. Group 3: Product Significance - Desensitization therapy is recognized as the only treatment that can potentially alter the natural course of allergic diseases [4]. - Andorra is a well-established desensitization product with unique efficacy benefits, while ACARIZAX is an innovative sublingual tablet that has been approved in multiple countries [4]. - The partnership aims to enhance the accessibility of these breakthrough products to meet the significant unmet clinical needs in China, where the penetration rate of desensitization therapy is below 4% [7].

Core Insights - Changchun High-tech announced a collaboration with Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China [2] - The partnership includes exclusive rights for Changchun Jin Sai Pharmaceutical Co., Ltd. to market three products developed by ALK in mainland China [2] Company Summary - Changchun High-tech's subsidiary, Changchun Jin Sai Pharmaceutical, will work with ALK-Abelló A/S on AIT products targeting house dust mites (HDM) [2] - The collaboration aims to leverage ALK's expertise in immunotherapy to enhance product offerings in the Chinese market [2] Industry Summary - The partnership signifies a growing trend in the immunotherapy sector, particularly in addressing allergic conditions in China [2] - The exclusive rights to market ALK's products may strengthen Changchun High-tech's position in the competitive pharmaceutical landscape [2]

根据双方合作协议约定，金赛药业将获得ALK的3款产品在中国大陆地区的独家权益，包括皮下注射用 屋尘螨变应原制剂(安脱达)、螨变应原皮肤点刺试剂盒(安刺)及尘螨变应原舌下片(ACARIZAX)，合作 权益期限至2039年12月31日止。金赛药业将支付首付款3,270万欧元，获得上述3款产品在中国大陆地区 的商业化权益。 长春高新（000661）(000661.SZ)公告，公司控股子公司——长春金赛药业有限责任公司(简称"金赛药 业")与丹麦ALK-AbellóA/S公司(简称"ALK")达成变应原特异性免疫治疗(AIT)产品合作，将在中国联合 开发并商业化ALK的屋尘螨(HDM)变应原特异性免疫治疗产品，并获得ALK自主开发的3款产品在中国 大陆范围内的独家代理权益。 ...